Flupentixol decanoate (BioDeep_00000179153)

   

human metabolite blood metabolite


代谢物信息卡片


2-(4-{3-[2-(trifluoromethyl)-9H-thioxanthen-9-ylidene]propyl}piperazin-1-yl)ethyl decanoic acid

化学式: C33H43F3N2O2S (588.2997174000001)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCCCCCCCCC(=O)OCCN1CCN(CCC=C2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
InChI: InChI=1S/C33H43F3N2O2S/c1-2-3-4-5-6-7-8-15-32(39)40-24-23-38-21-19-37(20-22-38)18-11-13-27-28-12-9-10-14-30(28)41-31-17-16-26(25-29(27)31)33(34,35)36/h9-10,12-14,16-17,25H,2-8,11,15,18-24H2,1H3

描述信息

同义名列表

8 个代谢物同义名

2-(4-{3-[2-(trifluoromethyl)-9H-thioxanthen-9-ylidene]propyl}piperazin-1-yl)ethyl decanoic acid; 2-(4-{3-[2-(trifluoromethyl)-9H-thioxanthen-9-ylidene]propyl}piperazin-1-yl)ethyl decanoate; 2-(4-{3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl}piperazin-1-yl)ethyl decanoate; Flupenthixol decanoate, (Z)-isomer; Flupentixol decanoic acid; Flupenthixol decanoate; Flupentixol decanoate; Depixol



数据库引用编号

5 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Loren Bailey, David Taylor. Estimating the optimal dose of flupentixol decanoate in the maintenance treatment of schizophrenia-a systematic review of the literature. Psychopharmacology. 2019 Nov; 236(11):3081-3092. doi: 10.1007/s00213-019-05311-2. [PMID: 31300829]
  • Robin Emsley, Laila Asmal, Bonginkosi Chiliza, Stefan du Plessis, Jonathan Carr, Martin Kidd, Anil K Malhotra, Matthijs Vink, Rene S Kahn. Changes in brain regions associated with food-intake regulation, body mass and metabolic profiles during acute antipsychotic treatment in first-episode schizophrenia. Psychiatry research. 2015 Aug; 233(2):186-93. doi: 10.1016/j.pscychresns.2015.06.014. [PMID: 26184461]
  • S Reeves, R Howard. Depot injections and nut allergy. The British journal of psychiatry : the journal of mental science. 2002 Feb; 180(?):188. doi: 10.1192/bjp.180.2.188. [PMID: 11823338]
  • K Wiener. A falling HbA1c is not necessarily an indicator of improving diabetes control. Annals of clinical biochemistry. 2001 Jul; 38(Pt 4):406-7. doi: 10.1258/0004563011900740. [PMID: 11471885]
  • E Tuninger, S Levander. Large variations of plasma levels during maintenance treatment with depot neuroleptics. The British journal of psychiatry : the journal of mental science. 1996 Nov; 169(5):618-21. doi: 10.1192/bjp.169.5.618. [PMID: 8932892]
  • K Kistrup, J Gerlach, T Aaes-Jørgensen, N E Larsen. Perphenazine decanoate and cis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients. Serum levels at the minimum effective dose. Psychopharmacology. 1991; 105(1):42-8. doi: 10.1007/bf02316862. [PMID: 1745710]
  • B Lipska, L Welbel, K Nurowska, B Szukalski. Radioreceptor assay in checking serum concentration in long-term treatment with cis(z)-flupenthixol decanoate. Activitas nervosa superior. 1987 Dec; 29(4):270-3. doi: NULL. [PMID: 3439426]
  • T G Dinan. Neuroleptic effects on platelet aggregation: a study in normal volunteers and schizophrenics. Psychological medicine. 1987 Nov; 17(4):875-81. doi: 10.1017/s0033291700000672. [PMID: 2893407]
  • J Turbott, J Villiger, L Hunter. Depot neuroleptic medication and serum levels by radioreceptor assay: prolactin concentration, electrocardiogram abnormalities and six-month outcome. The Australian and New Zealand journal of psychiatry. 1987 Sep; 21(3):327-38. doi: 10.1080/00048678709160929. [PMID: 3435373]
  • I B Cookson. The effects of a 50\% reduction of cis(z)-flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime. International clinical psychopharmacology. 1987 Apr; 2(2):141-9. doi: 10.1097/00004850-198704000-00008. [PMID: 3298419]
  • J C Levron, R Ropert. [Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics]. L'Encephale. 1987 Mar; 13(2):83-7. doi: . [PMID: 2885172]
  • L Farde, C Halldin, S Stone-Elander, G Sedvall. PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride. Psychopharmacology. 1987; 92(3):278-84. doi: 10.1007/bf00210831. [PMID: 2957716]
  • M W Jann, L Ereshefsky, S R Saklad. Clinical pharmacokinetics of the depot antipsychotics. Clinical pharmacokinetics. 1985 Jul; 10(4):315-33. doi: 10.2165/00003088-198510040-00003. [PMID: 2864156]
  • J K Saikia, A Jørgensen. Steady-state serum concentrations after cis (Z)-flupentixol decanoate in viscoleo. Psychopharmacology. 1983; 80(4):371-3. doi: 10.1007/bf00432123. [PMID: 6414008]
  • A Jørgensen, J Andersen, N Bjørndal, S J Dencker, L Lundin, U Malm. Serum concentrations of cis(Z)-flupentixol and prolactin in chronic schizophrenic patients treated with flupentixol and cis(Z)-flupentixol decanoate. Psychopharmacology. 1982; 77(1):58-65. doi: 10.1007/bf00436100. [PMID: 6812119]